These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 25223703)

  • 1. Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis.
    Yu T; Tao Y; Yang M; Chen P; Gao X; Zhang Y; Zhang T; Chen Z; Hou J; Zhang Y; Ruan K; Wang H; Hu R
    Cell Res; 2014 Oct; 24(10):1214-30. PubMed ID: 25223703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
    Dou QP; Zonder JA
    Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
    Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
    Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel proteasome inhibitors to overcome bortezomib resistance.
    Ruschak AM; Slassi M; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of bortezomib-adapted I-45 mesothelioma cells.
    Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
    Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
    Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
    J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
    Gonzalez-Santamarta M; Quinet G; Reyes-Garau D; Sola B; Roué G; Rodriguez MS
    Adv Exp Med Biol; 2020; 1233():153-174. PubMed ID: 32274756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin Disrupts Proteasome Bounce-Back Effect through Suppressing ZEB1/Nfe2l1 in Cholangiocarcinoma.
    Xiang Y; Jia M; Gao Y; Yang F; Wang T; Dai R; Wang M; Miao H
    Front Biosci (Landmark Ed); 2024 Mar; 29(3):106. PubMed ID: 38538281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
    Roeten MSF; van Meerloo J; Kwidama ZJ; Ter Huizen G; Segerink WH; Zweegman S; Kaspers GJL; Jansen G; Cloos J
    Cells; 2021 Mar; 10(3):. PubMed ID: 33802801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.
    Verbrugge SE; Assaraf YG; Dijkmans BA; Scheffer GL; Al M; den Uyl D; Oerlemans R; Chan ET; Kirk CJ; Peters GJ; van der Heijden JW; de Gruijl TD; Scheper RJ; Jansen G
    J Pharmacol Exp Ther; 2012 Apr; 341(1):174-82. PubMed ID: 22235146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.
    Zhou Y; Liu X; Xue J; Liu L; Liang T; Li W; Yang X; Hou X; Fang H
    J Med Chem; 2020 May; 63(9):4701-4715. PubMed ID: 32267687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibitors.
    Cvek B
    Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting bortezomib: development, application, adverse effects and future direction.
    Cao B; Li J; Mao X
    Curr Pharm Des; 2013; 19(18):3190-200. PubMed ID: 23151134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
    Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS
    Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.
    Shabaneh TB; Downey SL; Goddard AL; Screen M; Lucas MM; Eastman A; Kisselev AF
    PLoS One; 2013; 8(2):e56132. PubMed ID: 23460792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
    Ri M
    Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
    Niewerth D; Jansen G; Riethoff LF; van Meerloo J; Kale AJ; Moore BS; Assaraf YG; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
    Mol Pharmacol; 2014 Jul; 86(1):12-9. PubMed ID: 24737138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.
    Vaeteewoottacharn K; Kariya R; Matsuda K; Taura M; Wongkham C; Wongkham S; Okada S
    J Cancer Res Clin Oncol; 2013 Sep; 139(9):1551-62. PubMed ID: 23877657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.